(HealthDay)—Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced.
* This article was originally published here
This Blog Is Powered By The Life Technology™ News And Advertising Network. Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.
